This morning AstraZeneca announced that anifroumab flunked their late stage study. This was one of their main drivers of expected growth. If memory serves correct lupus was one of the potential issues that apabetalone may positively affect. Since there is now a gap in one of the future drivers for AZN maybe they will be looking to fill it. AZN owns Crestor that is now off patent. In previous studies apabetalone work best in conjunction with Rosuvastin ( Crestor ). We know they are familiar with us but not to what extent.
This story gets more interesting every day.
All IMO, dyoddÂ
tada
